» Articles » PMID: 29936596

Molecular Mechanisms of Hepatic Lipid Accumulation in Non-alcoholic Fatty Liver Disease

Overview
Publisher Springer
Specialty Biology
Date 2018 Jun 25
PMID 29936596
Citations 528
Authors
Affiliations
Soon will be listed here.
Abstract

Non-alcoholic fatty liver disease (NAFLD) is currently the world's most common liver disease, estimated to affect up to one-fourth of the population. Hallmarked by hepatic steatosis, NAFLD is associated with a multitude of detrimental effects and increased mortality. This narrative review investigates the molecular mechanisms of hepatic steatosis in NAFLD, focusing on the four major pathways contributing to lipid homeostasis in the liver. Hepatic steatosis is a consequence of lipid acquisition exceeding lipid disposal, i.e., the uptake of fatty acids and de novo lipogenesis surpassing fatty acid oxidation and export. In NAFLD, hepatic uptake and de novo lipogenesis are increased, while a compensatory enhancement of fatty acid oxidation is insufficient in normalizing lipid levels and may even promote cellular damage and disease progression by inducing oxidative stress, especially with compromised mitochondrial function and increased oxidation in peroxisomes and cytochromes. While lipid export initially increases, it plateaus and may even decrease with disease progression, sustaining the accumulation of lipids. Fueled by lipo-apoptosis, hepatic steatosis leads to systemic metabolic disarray that adversely affects multiple organs, placing abnormal lipid metabolism associated with NAFLD in close relation to many of the current life-style-related diseases.

Citing Articles

Metabolic dysfunction-associated steatotic liver disease in adults.

Huang D, Wong V, Rinella M, Boursier J, Lazarus J, Yki-Jarvinen H Nat Rev Dis Primers. 2025; 11(1):14.

PMID: 40050362 DOI: 10.1038/s41572-025-00599-1.


Association between relative fat mass and gallstones: a cross-sectional study based on NHANES 2017-2020.

Gao C, Li Y, Ren X, Han W Front Nutr. 2025; 12:1554659.

PMID: 40046759 PMC: 11879834. DOI: 10.3389/fnut.2025.1554659.


Motor protein KIF13B orchestrates hepatic metabolism to prevent metabolic dysfunction-associated fatty liver disease.

Miao G, Zhang W, Xu Y, Liu Y, Lai P, Guo J Mil Med Res. 2025; 12(1):11.

PMID: 40038775 PMC: 11877712. DOI: 10.1186/s40779-025-00594-3.


Bioactive small compounds effectively inhibit ChREBP overexpression to treat NAFLD and T2DM: A computational drug development approach.

Devnath H, Medha M, Islam M, Biswas P, Oisay D, Hossain A Heliyon. 2025; 11(4):e42477.

PMID: 40034298 PMC: 11872590. DOI: 10.1016/j.heliyon.2025.e42477.


Exploring the Putative Involvement of MALAT1 in Mediating the Beneficial Effect of Exendin-4 on Oleic Acid-Induced Lipid Accumulation in HepG2 Cells.

Khalifa O, Ayoub S, Arredouani A Biomedicines. 2025; 13(2).

PMID: 40002783 PMC: 11853215. DOI: 10.3390/biomedicines13020370.


References
1.
von Loeffelholz C, Docke S, Lock J, Lieske S, Horn P, Kriebel J . Increased lipogenesis in spite of upregulated hepatic 5'AMP-activated protein kinase in human non-alcoholic fatty liver. Hepatol Res. 2016; 47(9):890-901. DOI: 10.1111/hepr.12825. View

2.
Uyeda K, Repa J . Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. Cell Metab. 2006; 4(2):107-10. DOI: 10.1016/j.cmet.2006.06.008. View

3.
Zhang X, Xu C, Yu C, Chen W, Li Y . Role of endoplasmic reticulum stress in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol. 2014; 20(7):1768-76. PMC: 3930975. DOI: 10.3748/wjg.v20.i7.1768. View

4.
Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair K . Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology. 2002; 35(4):898-904. DOI: 10.1053/jhep.2002.32527. View

5.
Singh S, Allen A, Wang Z, Prokop L, Murad M, Loomba R . Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2014; 13(4):643-54.e1-9. PMC: 4208976. DOI: 10.1016/j.cgh.2014.04.014. View